Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
5.81
+0.18 (3.29%)
At close: Apr 28, 2026, 4:00 PM EDT
5.92
+0.11 (1.89%)
After-hours: Apr 28, 2026, 6:06 PM EDT
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Lexeo Therapeutics stock have an average target of 18.44, with a low estimate of 10 and a high estimate of 30. The average target predicts an increase of 217.38% from the current stock price of 5.81.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 13, 2026.
Analyst Ratings
The average analyst rating for Lexeo Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +192.60% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $10 | Strong Buy | Maintains | $13 → $10 | +72.12% | Jan 13, 2026 |
| Raymond James | Raymond James | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +330.29% | Dec 18, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +192.60% | Dec 11, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $19 | Buy | Initiates | $19 | +227.02% | Dec 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
14.09M
EPS This Year
-1.37
from -1.86
EPS Next Year
-1.39
from -1.37
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 57.8M | ||||||
| Avg | n/a | 14.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.08 | -0.80 | ||||||
| Avg | -1.37 | -1.39 | ||||||
| Low | -1.69 | -1.90 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.